In alignment with the Company’s clinical development plan, Jasper has obtained regulatory clearance to enroll a 180mg dose cohort (n=12) in the SPOTLIGHT study. Jasper expects to present full ...

The company anticipates reporting data from this study in the second half of 2022. “We are pleased to be moving forward in evaluating NYX-458 in patients suffering from cognitive impairment ...

Jasper expects to commence dosing patients in the fourth quarter of 2024 and to report initial data in the second half of 2025. “Clearance of the CTA for the asthma study is an important ...

the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper’s ...

Jasper Therapeutics (JSPR), announced that the first patient has been dosed in Jasper’s Phase 1b/2a clinical challenge study evaluating briquilimab in allergic asthma, called ETESIAN,Evaluating ...

Jasper is currently conducting clinical studies of briquilimab as a treatment in patients with CSU or with CIndU, and is planning to initiate a clinical study in patients with asthma. Briquilimab ...

Aptinyx Inc., a clinical-stage biopharmaceutical company, announced the initiation of a phase 2b study evaluating 50 mg QD of NYX-783 in 300 patients with post-traumatic stress disorder (PTSD). The ...

Across the overall study population, NYX-458 did not demonstrate clinically meaningful improvements over placebo on the study’s efficacy endpoints. The results do not support further development ...